Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Challenges in Duchenne muscular dystrophy

K E Davies1

  • 1Department of Biochemistry, University of Oxford, UK. kdavies@bioch.ox.ac.uk

Neuromuscular Disorders : NMD
|February 3, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Syncoilin is an intermediate filament protein in activated hepatic stellate cells.

Histochemistry and cell biology·2013
Same author

UTRN on chromosome 6q24 is mutated in multiple tumors.

Oncogene·2007
Same author

Utrophin upregulation in Duchenne muscular dystrophy.

Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology·2006
Same author

A and B utrophin in human muscle and sarcolemmal A-utrophin associated with tumours.

Neuromuscular disorders : NMD·2005
Same author

Regulation of utrophin in transgenic mice.

Neuromuscular disorders : NMD·2005
Same author

Stromal cell-derived receptor 2 and cytochrome b561 are functional ferric reductases.

Biochimica et biophysica acta·2003
Same journal

Aquatic training improves muscle strength and functional mobility in adults with myotonic dystrophy type 1: a pilot randomized trial.

Neuromuscular disorders : NMD·2026
Same journal

Severe dilated cardiomyopathy in females with dystrophinopathy : a case series of nine patients.

Neuromuscular disorders : NMD·2026
Same journal

A portrait of facioscapulohumeral muscular dystrophy through history: past milestones and future challenges on the road to understanding and treatment.

Neuromuscular disorders : NMD·2026
Same journal

Systematic review of outcome measures in facioscapulohumeral dystrophy (FSHD): validated, usable, and feasible tools for assessing function, performance, and strength.

Neuromuscular disorders : NMD·2026
Same journal

Longitudinal functional trajectories in Duchenne muscular dystrophy: outcome-specific patterns from a registry-based modelling study.

Neuromuscular disorders : NMD·2026
Same journal

HACD1-related congenital myopathy skeletal muscle MRI findings in a Brazilian cohort.

Neuromuscular disorders : NMD·2026
See all related articles

Recent advances have significantly improved understanding of muscular dystrophies, leading to new diagnostic tools and gene identification. The focus is now shifting towards developing effective therapies for these genetic muscle-wasting diseases.

Area of Science:

  • Genetics and Molecular Biology
  • Neurology and Musculoskeletal Disorders

Background:

  • Significant progress in understanding muscular dystrophies over the past seven years.
  • Development of prenatal diagnosis for Duchenne muscular dystrophy in the early 1980s.
  • Identification of a novel membrane complex following gene cloning in 1996.

Purpose of the Study:

  • To review the impact of recent genetic and molecular advances on muscular dystrophy.
  • To discuss the implications for clinical management and future therapeutic development.
  • To honor the contributions of Professor Alan Emery to the field.

Main Methods:

  • Review of scientific literature and historical data on muscular dystrophy research.
  • Analysis of gene cloning and identification of disease-related genes.

Related Experiment Videos

  • Examination of advancements in diagnostic techniques and therapeutic strategies.

    • Main Results:

    • Cloning of the Duchenne muscular dystrophy gene led to a deeper understanding of the disease.
    • Identification of genes responsible for autosomal muscular dystrophies.
    • Progress in understanding has paved the way for therapeutic interventions.

    Conclusions:

    • Advances in understanding muscular dystrophies are transforming clinical management.
    • The focus is shifting from diagnosis to the development of effective therapies.
    • Future prospects for treating muscular dystrophies are promising.